BioCentury | Nov 3, 2020
Finance

Nov. 3 Quick Takes: JW lists in Hong Kong; plus Fountain Healthcare’s €125M fund, and EMA reviewing GenSight, Vifor/ChemoCentryx programs

...GenSight Biologics S.A. (Euronext:SIGHT); and avacopan from Vifor Fresenius Medical Care Renal Pharma Ltd. and ChemoCentryx Inc....
...Complement receptor 5A BC Staff LUMEVOQ (GS010, RAAV2/2_ND4) Avacopan (CCX168, C5aR inhibitor) JW Therapeutics Co. Ltd. GenSight Biologics S.A. Vifor Pharma Ltd. ChemoCentryx Inc. Fountain...
BioCentury | Sep 18, 2020
Product Development

Sept. 17 Quick Takes: Another Tecfidera setback for Biogen; plus ChemoCentryx PDUFA date and Amytrx’s debut

...the Northern District of West Virginia (see “More Pressure on Biogen's Pipeline”).July PDUFA date for ChemoCentryx...
...million in series A funding. TARGETSC5a – Complement 5a BC Staff Tecfidera, dimethyl fumarate (bg-12, BG00012) Avacopan (CCX168, C5aR inhibitor) Biogen ChemoCentryx Inc. Amytrx...
BioCentury | Jul 22, 2020
Management Tracks

Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

...as CSO, succeeding interim CSO David Spellmeyer. Singh was SVP of research and pharmaceutics at ChemoCentryx Inc....
BioCentury | Jun 12, 2020
Finance

May’s momentum continues as Catalent, eight others price follow-ons

...not respond to inquiries regarding financial terms. The company’s stock fell $5.98 to $68.65 Thursday. ChemoCentryx Inc....
...and inflammatory diseases company’s Wednesday close of $60.25, when it proposed the offering after hours. ChemoCentryx’s...
...NASDAQ:IMUX), which raised $25 million Wednesday. Elizabeth S. Eaton, Staff Writer Moderna Inc. Guardant Health Inc. Allogene Therapeutics Inc. Catalent Inc. ChemoCentryx Inc. Fate...
BioCentury | May 19, 2020
Product Development

May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV

...ChemoCentryx therapy fails Phase II study in rare renal disorder ChemoCentryx Inc. (NASDAQ:CCXI) and partner Vifor Fresenius...
BioCentury | Jan 1, 2020
Financial News

Fourth quarter rally pushes biotech to strong finish

...such as Karuna Therapeutics Inc. (NASDAQ:KRTX), Myovant Sciences Inc. (NASDAQ:MYOV), Axsome Therapeutics Inc. (NASDAQ:AXSM) and ChemoCentryx Inc....
...Quintuples in Value” ; “Big Gain for Myovant” ; “Migraine Readout for Surging Axsome” ; “ChemoCentryx’s...
BioCentury | Nov 26, 2019
Clinical News

ChemoCentryx's valuation reaches nearly $1.8 billion after vasculitis readout

...to standard-of-care therapy in a Phase III trial to treat a rare form of vasculitis. ChemoCentryx Inc....
...cancer (see "Karuna Clears Bar" ; "Big Gain for Myovant" ). After market hours Monday, ChemoCentryx...
...improvements in kidney function and quality-of-life metrics. The study's results are to be included in ChemoCentryx's...
BioCentury | Nov 26, 2019
Company News

Nov. 25 Company Quick Takes: FDA approves GBT's sickle cell therapy; plus ChemoCentryx, Astellas, La Jolla, Sorrento, Aquestive

...Poised for Fresh Infusion of Hemoglobin-based Endpoints" ). ChemoCentryx soars on Phase III vasculitis data ChemoCentryx Inc....
...to reductions in glucocorticoid-related toxicity, improvements in kidney function and improvements in quality of life. ChemoCentryx...
...PDUFA date. Elizabeth S. Eaton, Staff Writer voxelotor (GBT440) Xtandi, enzalutamide (mdv3100, p-INN) Avacopan (CCX168, C5aR inhibitor) LJPC-401 Global Blood Therapeutics Inc. ChemoCentryx Inc. Astellas...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...heat-activated liposome Treat newly diagnosed, intermediate stage hepatocellular carcinoma (HCC) Phase III interim data 2H19 ChemoCentryx Inc....
BioCentury | Jun 5, 2019
Clinical News

InflaRx stumbles after C5a mAb fails in inflammatory skin disease study

...diseases. Fellow C5a company ChemoCentryx Inc. (NASDAQ:CCXI) lost $2.10 (19%) to $8.98 in afternoon trading Wednesday. ChemoCentryx...
Items per page:
1 - 10 of 191
BioCentury | Nov 3, 2020
Finance

Nov. 3 Quick Takes: JW lists in Hong Kong; plus Fountain Healthcare’s €125M fund, and EMA reviewing GenSight, Vifor/ChemoCentryx programs

...GenSight Biologics S.A. (Euronext:SIGHT); and avacopan from Vifor Fresenius Medical Care Renal Pharma Ltd. and ChemoCentryx Inc....
...Complement receptor 5A BC Staff LUMEVOQ (GS010, RAAV2/2_ND4) Avacopan (CCX168, C5aR inhibitor) JW Therapeutics Co. Ltd. GenSight Biologics S.A. Vifor Pharma Ltd. ChemoCentryx Inc. Fountain...
BioCentury | Sep 18, 2020
Product Development

Sept. 17 Quick Takes: Another Tecfidera setback for Biogen; plus ChemoCentryx PDUFA date and Amytrx’s debut

...the Northern District of West Virginia (see “More Pressure on Biogen's Pipeline”).July PDUFA date for ChemoCentryx...
...million in series A funding. TARGETSC5a – Complement 5a BC Staff Tecfidera, dimethyl fumarate (bg-12, BG00012) Avacopan (CCX168, C5aR inhibitor) Biogen ChemoCentryx Inc. Amytrx...
BioCentury | Jul 22, 2020
Management Tracks

Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

...as CSO, succeeding interim CSO David Spellmeyer. Singh was SVP of research and pharmaceutics at ChemoCentryx Inc....
BioCentury | Jun 12, 2020
Finance

May’s momentum continues as Catalent, eight others price follow-ons

...not respond to inquiries regarding financial terms. The company’s stock fell $5.98 to $68.65 Thursday. ChemoCentryx Inc....
...and inflammatory diseases company’s Wednesday close of $60.25, when it proposed the offering after hours. ChemoCentryx’s...
...NASDAQ:IMUX), which raised $25 million Wednesday. Elizabeth S. Eaton, Staff Writer Moderna Inc. Guardant Health Inc. Allogene Therapeutics Inc. Catalent Inc. ChemoCentryx Inc. Fate...
BioCentury | May 19, 2020
Product Development

May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV

...ChemoCentryx therapy fails Phase II study in rare renal disorder ChemoCentryx Inc. (NASDAQ:CCXI) and partner Vifor Fresenius...
BioCentury | Jan 1, 2020
Financial News

Fourth quarter rally pushes biotech to strong finish

...such as Karuna Therapeutics Inc. (NASDAQ:KRTX), Myovant Sciences Inc. (NASDAQ:MYOV), Axsome Therapeutics Inc. (NASDAQ:AXSM) and ChemoCentryx Inc....
...Quintuples in Value” ; “Big Gain for Myovant” ; “Migraine Readout for Surging Axsome” ; “ChemoCentryx’s...
BioCentury | Nov 26, 2019
Clinical News

ChemoCentryx's valuation reaches nearly $1.8 billion after vasculitis readout

...to standard-of-care therapy in a Phase III trial to treat a rare form of vasculitis. ChemoCentryx Inc....
...cancer (see "Karuna Clears Bar" ; "Big Gain for Myovant" ). After market hours Monday, ChemoCentryx...
...improvements in kidney function and quality-of-life metrics. The study's results are to be included in ChemoCentryx's...
BioCentury | Nov 26, 2019
Company News

Nov. 25 Company Quick Takes: FDA approves GBT's sickle cell therapy; plus ChemoCentryx, Astellas, La Jolla, Sorrento, Aquestive

...Poised for Fresh Infusion of Hemoglobin-based Endpoints" ). ChemoCentryx soars on Phase III vasculitis data ChemoCentryx Inc....
...to reductions in glucocorticoid-related toxicity, improvements in kidney function and improvements in quality of life. ChemoCentryx...
...PDUFA date. Elizabeth S. Eaton, Staff Writer voxelotor (GBT440) Xtandi, enzalutamide (mdv3100, p-INN) Avacopan (CCX168, C5aR inhibitor) LJPC-401 Global Blood Therapeutics Inc. ChemoCentryx Inc. Astellas...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...heat-activated liposome Treat newly diagnosed, intermediate stage hepatocellular carcinoma (HCC) Phase III interim data 2H19 ChemoCentryx Inc....
BioCentury | Jun 5, 2019
Clinical News

InflaRx stumbles after C5a mAb fails in inflammatory skin disease study

...diseases. Fellow C5a company ChemoCentryx Inc. (NASDAQ:CCXI) lost $2.10 (19%) to $8.98 in afternoon trading Wednesday. ChemoCentryx...
Items per page:
1 - 10 of 191